Foamix claims goal-win­ning suc­cess in twin piv­otal stud­ies for rosacea — shares spike

The roller coast­er ride that Foamix Phar­ma­ceu­ti­cals has tak­en in­vestors on is on an up­swing track this morn­ing. The biotech re­port­ed that its top­i­cal for­mu­la­tion of the an­tibi­ot­ic minocy­cline scored on the co-pri­ma­ry end­points in treat­ing in­flam­ma­to­ry le­sions caused by rosacea came through with pos­i­tive re­sults.

The Is­raeli com­pa­ny’s shares $FOMX gy­rat­ed up­ward Wednes­day morn­ing, jump­ing about 25% in pre-mar­ket trad­ing. It’s still un­der the $6 price the biotech hit when it launched an IPO on Nas­daq in 2014.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER